Inovio Pharmaceuticals Inc vs Kingsoft Cloud Holdings Limited — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Kingsoft Cloud Holdings Limited trades at $10.14 (market cap $3.01B). The key difference: Kingsoft Cloud Holdings Limited is far larger — about 33.7× Inovio Pharmaceuticals Inc's market cap, and Kingsoft Cloud Holdings Limited is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | KC | |
|---|---|---|
Market Cap | $89.27M | $3.01B |
Sector | Health | Technology |
52-Week High | $2.87 | $18.21 |
52-Week Low | $1.05 | $8.58 |
Enterprise Value | $60.28M | $3.32B |
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Kingsoft Cloud (KC) trades at $10.04, up 5.24% today, showing strong momentum despite a bearish technical signal. The company reported Q1 2026 revenue growth of 37% year-over-year, driven by AI cloud demand, though profitability remains challenged with a -9.39% net margin. Analyst sentiment is positive with 70% buy ratings, citing potential from AI expansion and trade easing between the U.S. and China.
KC presents a growth opportunity in cloud and AI services with strong revenue acceleration, but investors face risks from persistent losses, high capital expenditure, and competitive pressures. The stock's outlook hinges on margin improvement from AI investments and sustained demand, making it suitable for growth-oriented investors tolerant of near-term volatility.
Trailing returns across standard periods
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →